{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-330730","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2026-08-03T20:47:12+00:00","discovered_at":"2026-08-03T20:48:03.411474+00:00","generated_at":"2026-08-03T20:48:08.935999+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cue Biopharma appoints James Ahlers as CFO effective July 30, 2026","bullets":["James Ahlers appointed CFO of Cue Biopharma effective July 30, 2026.","Base salary $450,000; eligible for discretionary annual bonus target of 45% of base salary.","Received inducement option for 51,000 shares at $30.40 and RSU for 25,500 shares, vesting quarterly over 4 years.","Previously served as CFO of Intarcia Therapeutics, consulting CFO at Danforth Advisors, and roles at Intensity Therapeutics and RenovoRx.","Severance: 9 months base plus prorated target bonus on qualifying termination; change-in-control triggers full equity acceleration."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-330730","json":"https://secwatch.observer/filing/0001193125-26-330730.json","markdown":"https://secwatch.observer/filing/0001193125-26-330730.md","text":"https://secwatch.observer/filing/0001193125-26-330730.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/0001193125-26-330730-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/d134183d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:48:08.935999+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"431fbe2f20","claim":"James Ahlers was appointed as Chief Financial Officer at Cue Biopharma, Inc..","evidence_excerpt":"On August 3, 2026, Cue Biopharma, Inc. (the “Company”) announced that the Company’s Board of Directors (the “Board”) appointed James Ahlers as the Company’s Chief Financial Officer, effective as of July 30, 2026 (the “Effective Date”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645460/000119312526330730/0001193125-26-330730-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}